As you mentioned, genotype 2 responds readily to the current interferon/
ribavirin combo. You have 80-90% odds of success, versus the 40-45 % success rate with genotype 1, which is the most prevalent strain in North America; however, they both have the potential for deadly results.
A biopsy is the most accurate method of determining disease progression; unlike Hep B and HIV, viral load doesn’t *necessarily* correlate with disease severity.